High potency dihydroergotamine compositions

Details High potency dihydroergotamine compositions High potency dihydroergotamine compositions

2006-06-13

2006-06-13

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S220000

Reexamination Certificate

active

07060694

ABSTRACT:
The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.

REFERENCES:
patent: 4138565 (1979-02-01), Ehrhardt et al.
patent: 5169849 (1992-12-01), Kiechel et al.
patent: 5643604 (1997-07-01), Angeles Uribe et al.
patent: 5733572 (1998-03-01), Unger et al.
patent: 6495535 (2002-12-01), Plachetka et al.
patent: 881 967 (1980-06-01), None
patent: 25 55 481 (1977-06-01), None
patent: 32 27 122 (1984-01-01), None
patent: 074 620 (1983-03-01), None
patent: 2 399 248 (1979-03-01), None
patent: 1 596 948 (1977-08-01), None
patent: 175 167 (1979-10-01), None
patent: 178 090 (1981-07-01), None
patent: 219 461 (1993-01-01), None
patent: WO 96/25190 (1996-08-01), None
Becker, et al., “Effectiveness of Subcutaneous Dihydroergotamine by Home Injection for Migraine,”Headache36:144-148 (1996).
Belgrade, et al., “Comparison of Single-Dose Meperidine, Butorphanol, and Dihydroergotamine in the Treatment of Vascular Headache,”Neurology39:590-592 (1989).
Klapper, et al., “Clinical Experience with Patient Administered Subcutaneous Dihydroergotamine Mesylate in Refractory Headaches,”Headache32:21-23 (1992).
Raskin, “Repetitive Intravenous Dihydroergotamine as Therapy for Intractable Migraine,”Neurology36:995-997 (1986).
Saadah, “Abortive Headache Therapy with Intramuscular Dihydroergotamine,”Headache32:18-20 (1992).
Schran, et al., “Bioequivalence and Safety of Subcutaneously and Intramusculary Administered Dihydroergotamine in Healthy Volunteers,”Curr. Ther. Res.55:1501-1508 (1994).
Silberstein, et al., “Repetitive Intravenous DHE in the Treatment of Refractory Headache,”Headache30:334-339 (1990).
Welch, “Drug Therapy of Migraine,”New Eng. J. Med.329:1476-1483 (1993).
Winner, et al., “A Double-Blind Study of Subcutaneous Dihydroergotamine vs. Subcutaneous Sumatriptan in the Treatment of Acute Migraine,”Arch. Neurol.53:180-184 (1996).
Winner, et al., “Office-Based Treatment of Acute Migraine with Dihydroergotamine Mesylate,”Headache33:471-475 (1993).
Physicians' Desk Reference 53 Edition 1999; Dec. 1998, pp. 2059-2063.
Drug Facts and Comparisons, 1985, pp. 257c.

Affiliated with

Also associated with

Rating

High potency dihydroergotamine compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High potency dihydroergotamine compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High potency dihydroergotamine compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3707375